MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia

Xi Ming; Wanying Liu; Jiaying Wu; Shu Yan; Shuai Su; Yu Wang; Rubing Zheng; Yi Xiao

doi:10.1186/s13062-026-00762-y

March 26, 2026Biology DirectOpen Access

MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to explore the role of MEF2A in promoting drug resistance and cancer progression in acute myeloid leukemia.
Investigated the relationship between MEF2A and ZDHHC20 expression levels.
Analyzed the activation of the NF-κB pathway in response to MEF2A.
Evaluated the impact of targeting the MEF2A/ZDHHC20 axis on drug resistance.
MEF2A enhances ZDHHC20 expression, leading to NF-κB pathway activation.
Doxorubicin sensitivity is reduced in models where MEF2A is active.
Targeting MEF2A/ZDHHC20 shows promise for overcoming drug resistance.

Implication

Demonstrates how MEF2A activates a pathway that reduces drug sensitivity in AML, suggesting a potential treatment target.

Abstract

MEF2A promoted AML progression and DOX resistance by transcriptionally upregulating ZDHHC20, thereby activating the NF-κB pathway. Targeting the MEF2A/ZDHHC20 axis represents a promising therapeutic strategy to overcome chemoresistance and improve clinical outcomes in AML patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ming et al. (2026) studied this question.

synapsesocial.com/papers/69c771198bbfbc51511e1009 https://doi.org/10.1186/s13062-026-00762-y

View Full Paper

Ask AI

Bookmark

Share

MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia

Key Points

Implication

Abstract

Discussion

Cite This Study

MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading